

**Impact of safinamide in Parkinson's disease: real-life findings from the HELP network**

*Andrea Pilotto*<sup>1</sup>, M. Bianchi<sup>2</sup>, F. Pepe<sup>3</sup>, D. Alimonti<sup>4</sup>, F. Pisano<sup>5</sup>, V. de Giuli<sup>6</sup>, J.M. Melgari<sup>7</sup>, A. Micheli<sup>8</sup>, M.C. Rizzetti<sup>9</sup>, S. Gipponi<sup>1</sup>, E. Cottini<sup>1</sup>, C. Zatti<sup>1</sup>, A. Lupini<sup>1</sup>, B. Bigni<sup>3</sup>, E. Magni<sup>3</sup>, M. Sessa<sup>4</sup>, M. Turla<sup>5</sup>, B. Ferrero<sup>7</sup>, A. Ciccone<sup>10</sup>, A. Padovani<sup>1</sup>

<sup>1</sup>Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

<sup>2</sup>Neurology Unit, ASST Esine Hospital, Esine, Italy

<sup>3</sup>Neurology Unit, Poliambulanza Hospital, Brescia, Italy

<sup>4</sup>Neurology Unit, Papa San Giovanni Hospital, Bergamo, Italy

<sup>5</sup>Neurology Rehabilitation Unit, San Marco Clinic, Zingonia-Osio Sotto, Italy

<sup>6</sup>Neurology Unit, ASST Cremona Hospital, Cremona, Italy

<sup>7</sup>Neurology Unit, ASST Treviglio, Hospital, Treviglio, Italy

<sup>8</sup>San Francesco Hospital, Bergamo, Italy

<sup>9</sup>Parkinson's Disease Rehabilitation Centre, FERB ONLUS – S. Isidoro Hospital, Trescore Balneario (BG), Italy

<sup>10</sup>Neurology Units, ASST Mantova Hospital, Mantova, Italy

*Background:* Several pharmacological strategies have been proposed for the treatment of motor fluctuations for motor fluctuations in Parkinson's disease (PD). Still the short and long-term of safinamide and other treatments in real-life scenario is theme of debate.

*Objective:* To evaluate the short and long-term impact of safinamide in Parkinson's disease in real life multicenter setting.

*Methods:* Data collected from digital platform from multicenter study were collected. PD patients consecutively enrolled with motor fluctuations who underwent safinamide treatment were selected and motor/non- motor assessment was evaluated before and after treatment in short term and long-term.

*Results:* Six-hundred-forty-nine patients were included in the network- of them, 313 presented motor fluctuations and 178 were treated with safinamide (Mean age  $68.7 \pm 8.$ , mean disease duration  $8.1 \pm 5.8$ , mean UPDRS-III  $24.2 \pm 14.8$  in ON). Follow-up data were available for 112 and 89 subjects for short and long-term evaluation.

The improvement in global motor function and its impact in activities of daily living was significant at 3,6, 12 and 24 months. Longer response was associated with shorter onset of motor complication, independently from age, sex and disease severity.

*Conclusions:* Safinamide showed long-term benefit for motor complications in Parkinson's disease. Further studies are needed in order to confirm the association with early fluctuations with longer treatment benefit.